{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:00:31Z","timestamp":1774436431024,"version":"3.50.1"},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T00:00:00Z","timestamp":1611532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Development Research"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite vigorous efforts, the COVID\u201019 pandemic continues to take a toll on the global health. The contemporary therapeutic regime focused on the viral spike proteins, viral 3CL protease enzyme, immunomodulation, inhibition of viral replication, and providing a symptomatic relief encouraged the repurposing of drugs to meet the urgency of treatment. Similarly, the representative drugs that proved beneficial to alleviate SARS\u2010CoV\u20101, MERS\u2010CoV, HIV, ZIKV, H1N1, and malarial infection in the past presented a sturdy candidature for ameliorating the COVID\u201019 therapeutic doctrine. However, most of the deliberations for developing effective pharmaceuticals proved inconsequential, thereby encouraging the identification of new pathways, and novel pharmaceuticals for capping the COVID\u201019 infection. The COVID\u201019 contagion encompasses a burst release of the cytokines that increase the severity of the infection mainly due to heightened immunopathogenicity. The pro\u2010inflammatory metabolites, COX\u20102, cPLA2, and 5\u2010LOX enzymes involved in their generation, and the substrates that instigate the origination of the innate inflammatory response therefore play an important role in intensifying and worsening of the tissue morbidity related to the coronavirus infection. The deployment of representative drugs for inhibiting these overexpressed immunogenic pathways in the tissues invaded by coronaviruses has been a matter of debate since the inception of the pandemic. The effectiveness of NSAIDs such as Aspirin, Indomethacin, Diclofenac, and Celecoxib in COVID\u201019 coagulopathy, discouraging the SARS viral replication, the inflammasome deactivation, and synergistic inhibition of H5N1 viral infection with representative antiviral drugs respectively, have provided a silver lining in adjuvant COVID\u201019 therapy. Since the anti\u2010inflammatory NSAIDs and COXIBs mainly function by reversing the COX\u20102 overexpression to modulate the overproduction of pro\u2010inflammatory cytokines and chemokines, these drugs present a robust treatment option for COVID\u201019 infection. This commentary succinctly highlights the various claims that support the status of immunomodulatory NSAIDs, and COXIBs in the adjuvant COVID\u201019 therapy.<\/jats:p>","DOI":"10.1002\/ddr.21794","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T01:34:36Z","timestamp":1611624876000},"page":"469-473","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Targeting cyclooxygenase enzyme for the adjuvant <scp>COVID<\/scp>\u201019 therapy"],"prefix":"10.1002","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9412-9424","authenticated-orcid":false,"given":"Parteek","family":"Prasher","sequence":"first","affiliation":[{"name":"UGC Sponsored Centre for Advanced Studies, Department of Chemistry Guru Nanak Dev University  Amritsar India"},{"name":"Department of Chemistry University of Petroleum &amp; Energy Studies  Dehradun India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mousmee","family":"Sharma","sequence":"additional","affiliation":[{"name":"UGC Sponsored Centre for Advanced Studies, Department of Chemistry Guru Nanak Dev University  Amritsar India"},{"name":"Department of Chemistry Uttaranchal University  Dehradun India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Gunupuru","sequence":"additional","affiliation":[{"name":"Department of Chemistry University of Petroleum &amp; Energy Studies  Dehradun India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,1,25]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350601100803"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104849"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00050"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.486301"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/9550"},{"key":"e_1_2_5_7_1","first-page":"CD012852","article-title":"Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss","volume":"5","author":"Hamuly\u00e1k E. N.","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.561674"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-02941-w"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-020-0485-4"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109975"},{"key":"e_1_2_5_12_1","article-title":"Hypertension and renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with Covid\u201019","author":"Ip A.","year":"2020","journal-title":"medRxiv"},{"key":"e_1_2_5_13_1","article-title":"Breakthrough: Ibuprofen\/ nitazoxanide\/ azithromycin: A battle changer personalized COVID\u201019 telemedicine five days protocol","author":"Kelleni M.","year":"2020","journal-title":"Authorea"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110982"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/uog.22049"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107966"},{"key":"e_1_2_5_17_1","first-page":"1517","article-title":"SARS\u2010CoV\u20102 and viral sepsis: Observations and hypotheses","volume":"395","author":"Li H.","year":"2020","journal-title":"Hypothesis"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1185"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11262-005-0070-4"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.04.024"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.14134"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14888"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00038.2015"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00953-0"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30894-1"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.925775"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1159"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.24.14540"},{"key":"e_1_2_5_29_1","first-page":"417","article-title":"Developmental perspectives of the drugs targeting enzyme instigated inflammation: A mini review","volume":"28","author":"Prasher P.","year":"2019","journal-title":"Drug Development Research"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000375362"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008975"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15206"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13501"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc11886"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmal.2020.04.002"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1704099114"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.recesp.2020.04.006"}],"container-title":["Drug Development Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddr.21794","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ddr.21794","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddr.21794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:46:51Z","timestamp":1760345211000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/ddr.21794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,25]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1002\/ddr.21794"],"URL":"https:\/\/doi.org\/10.1002\/ddr.21794","archive":["Portico"],"relation":{},"ISSN":["0272-4391","1098-2299"],"issn-type":[{"value":"0272-4391","type":"print"},{"value":"1098-2299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,25]]},"assertion":[{"value":"2020-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}